Staff Pick /Features
ISAL 2017: Developments in acute leukemias
The International Symposium on Acute Leukemias (ISAL) 2017 was, as always, filled with data, scientific developments and debate. To capture…
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
5 months
The bone marrow mesenchymal stem cell: exploring its role in MGUS and multiple myeloma
Multiple myeloma (MM) is an incurable malignant disease of plasma cells, representing the most severe form of paraproteinaemia. In most…
Multiple Myeloma
10 months
TIDEL II trial: uncovering the predictive value of ABCB1 in determining the long-term response to imatinib in CML patients
Adelaide researchers based at the South Australian Health and Medical Research Institute (SAHMRI) have demonstrated the significance of early increases…
Chronic Myeloid Leukemia
1 year
ASCO/EHA 2016: Combination therapies change the standard of care in multiple myeloma
As usual, the ASCO Annual Meeting and the EHA Annual Congress were a hub of activity, data and discussion. We…
Multiple Myeloma
Promoted Post
1 year
Positive Phase III results for plitidepsin
Plitidepsin (also known as dehydrodidemnin B) is a first-in-class drug originally obtained from the sea squirt Aplidium albicans.[1] Plitidepsin specifically…
Multiple Myeloma
1 year
